These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Coleman CI; Weeda ER; Nguyen E; Bunz TJ; Sood NA Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):328-329. PubMed ID: 29121212 [No Abstract] [Full Text] [Related]
26. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
27. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. McCarty D; Robinson A Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211 [TBL] [Abstract][Full Text] [Related]
28. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Albert NM Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340 [TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903 [TBL] [Abstract][Full Text] [Related]
30. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Reddy P; Giugliano RP J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084 [TBL] [Abstract][Full Text] [Related]
31. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Paikin JS; Manolakos JJ; Eikelboom JW Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284 [TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. ROCKET AF Study Investigators Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881 [TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. Spencer RJ; Amerena JV Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914 [TBL] [Abstract][Full Text] [Related]
36. New oral anticoagulants for patients with nonvalvular atrial fibrillation. Holden A; Azimi N; Forest CP JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Sun Y; Hu D; Stevens S; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Fox KAA; Patel MR Thromb Res; 2017 Aug; 156():184-190. PubMed ID: 28433206 [TBL] [Abstract][Full Text] [Related]
38. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Berman JP; Halperin JL Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966 [TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. Ahrens I; Bode C Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192 [TBL] [Abstract][Full Text] [Related]
40. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]